<DOC>
	<DOCNO>NCT02833974</DOCNO>
	<brief_summary>This study ass whether Toll like receptor 7 ( TLR7 ) -mediated pharmacology , intranasal ( i.n . ) GSK2245035 20 nanogram ( ng ) administer weekly period 8 week , lead reduce allergic reactivity lower airways subject mild allergic asthma . This randomised , double-blind ( sponsor open ) , placebo-controlled , parallel group , 8-week treatment study . The study consist screen period approximately 4 week ( involve two screen visit ) , blind treatment period 8 week , follow follow-up period 3 month . The total duration study subject therefore maximum approximately 6 month .</brief_summary>
	<brief_title>Effect GSK2245035 Allergen-induced Asthmatic Response</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion Criteria Between 18 65 year age inclusive , time signing informed consent . Diagnosis asthma , define history respiratory symptom wheeze , shortness breath , chest tightness cough vary time intensity , together variable expiratory airflow limitation least 6 month prior screen Current asthma therapy . Intermittent shortacting betaagonist ( SABA ) alone ( average 2 day per week ) Positive skin prick test ( 3 mm great negative control ) common perennial seasonal aeroallergen ( ) ( i.e. , house dust mite , cat dander , grass pollen ) screen Prebronchodilator FEV1 &gt; 70 % predict normal Screening Visit 1 EAR &gt; =20 % FEV1 decrease 5 30 minute final allergen concentration obtain screen bronchial allergen challenge ( BAC ) ( decrease relative saline ) LAR three FEV1 decrease &gt; = 15 % 4 10 hour final allergen concentration obtain screen bronchial allergen challenge , two FEV1 decrease consecutive time point ( decrease relative saline ) Subjects current nonsmoker ( define use tobacco product 6month period precede screen visit ) pack history &lt; 10 pack year . Number pack year = ( number cigarette per day/20 ) x number year smoke Bodyweight &gt; = 45kilograms ( kg ) Male OR female nonreproductive potential Male subject female partner child bear potential complying contraception requirement time first dose study medication final followup visit : Vasectomy documentation azoospermia , male condom plus partner use one follow contraceptive option : Contraceptive subdermal implant , Intrauterine device intrauterine system , Oral contraceptive , either combined progestogen alone , Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch . This allinclusive list method meet follow GSK definition highly effective : failure rate le 1 % per year use consistently correctly , applicable , accordance product label . For nonproduct method ( e.g. , male sterility ) , investigator determines consistent correct use . The GSK definition base definition provide International Conference Harmonization Technical Requirements Registration Pharmaceuticals Human Use ( ICH ) . The investigator responsible ensure subject understand properly use method contraception A female subject eligible participate pregnant , ( confirm negative [ serum urine ] human chorionic gonadotrophin [ hCG ] test ) , lactate follow condition applies : Nonreproductive potential : define premenopausal females one following Documented tubal ligation , Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , Hysterectomy , Documented Bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause [ refer laboratory reference range confirmatory level ] ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment Capable give sign informed consent Exclusion Criteria Alanine transaminase ( ALT ) &gt; 2xUpper Limit Normal ( ULN ) bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Heart rate correct QT interval ( QTc ) &gt; 450 millisecond ( msec ) QTc &gt; 480 msec subject Bundle Branch Block Asthma exacerbation require treatment oral corticosteroid hospitalization within 3 month prior screen History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure within last 10 year Evidence concurrent respiratory disease pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , allergic bronchopulmonary aspergillosis , cystic fibrosis , bronchopulmonary dysplasia , respiratory abnormality asthma Other concurrent diseases/abnormalities : A subject must clinically significant , uncontrolled condition disease state , opinion investigator , would put safety subject risk study participation would confound interpretation efficacy result condition/disease exacerbate study Respiratory tract infection resolve within 2 week prior screen Treatment intranasal steroid , inhale corticosteroid ( ICS ) without longacting beta2agonist ( LABA ) , treatment nonICS controller asthma medication ( i.e. , leukotriene modifier , methylxanthines ) within 4 week prior screen Use longacting antihistamine within 7 day ' shortacting antihistamine within 72 hour prior screen skin prick test Treatment systemic corticosteroid within 6 week prior screen Use inhaled SABAs rescue treatment average 2 day per week History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 unit male female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( ~240 mililiter [ ml ] ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit Patient know intolerant salbutamol albuterol History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment A positive prestudy drug/alcohol screen A positive test Human Immunodeficiency Virus ( HIV ) antibody Where participation study would result donation blood blood product excess 500 mL within 56 day period The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Exposure 4 investigational medicinal product within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GSK2245035</keyword>
	<keyword>TLR7 agonist</keyword>
	<keyword>allergic asthma</keyword>
	<keyword>FEV1</keyword>
</DOC>